QNCX (Quince Therapeutics) Accounts Payable: $5.39 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

QNCX Quince Therapeutics Inc QNCX
25 GF Score
Price $23.03
! 2 Warning Signs
View Full Analysis

What is Quince Therapeutics Accounts Payable?

Quince Therapeutics QNCX +4.68% 25 Accounts Payable is $5.39 Mil as of Mar. 2026. GuruFocus rates QNCX with a GF Score™ of 25/100. The stock has 2 warning signs investors should review.

Quince Therapeutics's Accounts Payable for the quarter that ended in Mar. 2026 was $5.39 Mil.

Quince Therapeutics's quarterly Accounts Payable declined from Sep. 2025 ($3.40 Mil) to Dec. 2025 ($2.22 Mil) but then increased from Dec. 2025 ($2.22 Mil) to Mar. 2026 ($5.39 Mil).

Quince Therapeutics's annual Accounts Payable increased from Dec. 2023 ($2.03 Mil) to Dec. 2024 ($2.90 Mil) but then declined from Dec. 2024 ($2.90 Mil) to Dec. 2025 ($2.22 Mil).

Quince Therapeutics Accounts Payable Related Terms

Quince Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Quince Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Quince Therapeutics Accounts Payable Chart

Quince Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only 4.91 0.57 2.03 2.90 2.22

Quince Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.01 1.76 3.40 2.22 5.39
QNCX
25GF Score
Quince Therapeutics Inc QNCX
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Quince Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $5.39 Mil mean?
Quince Therapeutics (QNCX) has a Accounts Payable of $5.39 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Quince Therapeutics and its competitors.
Is Quince Therapeutics' Accounts Payable too high?
Quince Therapeutics' current Accounts Payable is $5.39 Mil. Overall, Quince Therapeutics has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Quince Therapeutics' Accounts Payable compare to LPCN and NXTC?
Quince Therapeutics' Accounts Payable of $5.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Quince Therapeutics and its competitors. Quince Therapeutics's current Accounts Payable is $5.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quince Therapeutics stock overvalued right now?
Quince Therapeutics (QNCX) has a current Accounts Payable of $5.39 Mil. The current Accounts Payable is $5.39 Mil. Quince Therapeutics' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Quince Therapeutics (QNCX), the current Accounts Payable is $5.39 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Quince Therapeutics Business Description

Address 611 Gateway Boulevard, Suite 273, South San Francisco, CA, USA, 94080
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
25GF Score

Get the complete analysis for QNCX

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.03
Price